UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

The New England journal of medicine, 2014-05, Vol.370 (21), p.1993-2001

2014

Volltextzugriff (PDF)

Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels

Journal of viral hepatitis, 2015-12, Vol.22 (12), p.977-982

2015

Volltextzugriff (PDF)

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

Infectious diseases (London, England), 2019-02, Vol.51 (2), p.131-139

2019

Volltextzugriff (PDF)

Proteomic evidence of vesatolimod-induced enhancement of "cross-talk" between innate and adaptive immune cells in HIV controllers on ART

Journal of the International AIDS Society, 2021-07, Vol.24 (S4), p.8

2021

Volltextzugriff (PDF)

Long-acting subcutaneous lenacapavir dosed every six months as part of a combination regimen in treatment-naive people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study

Journal of the International AIDS Society, 2021-07, Vol.24 (S4), p.13

2021

Volltextzugriff (PDF)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation

Hepatology communications, 2018-12, Vol.2 (12), p.1446-1450

2018

Volltextzugriff (PDF)

Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial

HEPATOLOGY, 2017, Vol.66, p.639A

2017

Volltextzugriff (PDF)

Thoracic Echinococcosis

The New England journal of medicine, 2003-02, Vol.348 (6), p.528-528

2003

Volltextzugriff (PDF)

EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR plus RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL

JOURNAL OF HEPATOLOGY, 2014, Vol.60 (1), p.S452

2014

Volltextzugriff (PDF)

Sofosbuvir plus Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial

HEPATOLOGY, 2013, Vol.58, p.733A

2013

Volltextzugriff (PDF)

Characterization and use of a digital light projector for vision research

Vision research (Oxford), 2001-02, Vol.41 (4), p.427-439

2001

Volltextzugriff (PDF)

Sectoral Shifts and Cyclical Unemployment Reconsidered

The Quarterly journal of economics, 1993-02, Vol.108 (1), p.219-243

1993

Volltextzugriff (PDF)

Treatment of winter depression with a portable, head-mounted phototherapy device

Progress in neuro-psychopharmacology & biological psychiatry, 1990, Vol.14 (4), p.569-578

1990

Volltextzugriff (PDF)

Infrared spectra of adsorbed propyne

Journal of catalysis, 1974, Vol.32 (1), p.148-154

1974

Volltextzugriff (PDF)

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(11)
Tagungsberichte
(3)

Sprache

Englisch
(14)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

Proteomic evidence of vesatolimod-induced enhancement of "cross-talk" between innate and adaptive immune cells in HIV controllers on ART

Long-acting subcutaneous lenacapavir dosed every six months as part of a combination regimen in treatment-naive people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation

Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial

Thoracic Echinococcosis

EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR plus RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL

Sofosbuvir plus Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial

Characterization and use of a digital light projector for vision research

Sectoral Shifts and Cyclical Unemployment Reconsidered

Treatment of winter depression with a portable, head-mounted phototherapy device

Infrared spectra of adsorbed propyne

Suchergebnisse filtern